Univercells S.A. has acquired SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through a robust, scalable and automated DNA synthesis technology resulting in one-step generation of long DNA fragments, in large quantities, with high purity, in a cGMP-compliant setup.   SynHelix’s offering will complement the RNA platform being developed by Quantoom Biosciences SA (Quantoom), the Univercells affiliate that is developing an end-to-end RNA production technology...